Laboratory of Cell and Molecular Tumor Biology and Bioactive Compounds, São Francisco University, Bragança Paulista, SP, Brazil.
Laboratory of Human and Medical Genetics, São Francisco University, Bragança Paulista, SP, Brazil.
Hum Vaccin Immunother. 2021 Nov 2;17(11):3989-4004. doi: 10.1080/21645515.2021.1955607. Epub 2021 Aug 5.
Brazil is one of the epicenters of COVID-19 pandemic and faces several hindrances to make his COVID-19 vaccination plan efficient.
The Brazilian COVID-19 vaccination plan was evaluated and the hindrances to make the COVID-19 vaccination plan efficient were described and discussed.
High territorial extension might contribute to a delay on the COVID-19 vaccination, due to difficulty in delivering vaccines to furthest Brazilian states and to all the interior cities. The choice among the vaccines should be done based on the type of storage and must consider the transport conditions necessary to maintain its effectiveness. The indigenous individuals were included with health-care workers as the first group to be vaccinated, inflaming the number of vaccines doses distributed in states where the indigenous population have higher prevalence. The antivaccine movement and the politicization of the vaccine are also hindrances to be overcome in Brazil. The COVID-19 incidence or mortality rate and the distribution of intensive care units (ICUs) are not a criterion to distribute the vaccines, as we did not identify a correlation between these markers and the number of vaccines. However, a strong or very strong correlation occurred between the number of COVID-19 vaccines and the number of COVID-19 cases, deaths by COVID-19, gross domestic product, as well as populational density. A total of 83,280,475 doses of COVID-19 vaccines were distributed in Brazil. In the first dose, the Coronavac (Sinovac™), AZD1222 (AstraZeneca/Oxford™), and BNT162b (Pfizer/BioNTech™) vaccines were responsible to vaccinate, respectively, 9.61%, 6.69%, and 0.35% of the Brazilian population. In the second dose, the Coronavac, AZD1222, and BNT162b vaccines were responsible to vaccinate, respectively, 7.52%, 0.53%, and <0.01% of the Brazilian population.
The Federal Government must evaluate the hindrances and propose solutions to maximize the immunization against COVID-19 on Brazil.
巴西是 COVID-19 大流行的中心之一，在实施 COVID-19 疫苗接种计划时面临诸多障碍。
评估了巴西 COVID-19 疫苗接种计划，并对实施 COVID-19 疫苗接种计划的障碍进行了描述和讨论。
巴西领土面积广阔，可能会延迟 COVID-19 疫苗的接种工作，因为向巴西最偏远的州和所有内陆城市运送疫苗存在困难。疫苗的选择应基于储存类型，并必须考虑到维持其有效性所需的运输条件。与医护人员一起，将原住民纳入第一批接种疫苗的人群，这导致在原住民人口较多的州分配的疫苗剂量增加。反疫苗运动和疫苗的政治化也是巴西需要克服的障碍。COVID-19 的发病率或死亡率以及重症监护病房（ICU）的分布不是分配疫苗的标准，因为我们没有发现这些指标与疫苗数量之间存在相关性。然而，COVID-19 疫苗的数量与 COVID-19 病例、COVID-19 死亡人数、国内生产总值以及人口密度之间存在很强或非常强的相关性。巴西共分发了 83280475 剂 COVID-19 疫苗。在第一剂中，分别由科兴中维（Coronavac）、阿斯利康（AZD1222）和辉瑞/BioNTech（BNT162b）疫苗为 9.61%、6.69%和 0.35%的巴西人口接种。在第二剂中，科兴中维、阿斯利康和辉瑞/BioNTech 疫苗分别为 7.52%、0.53%和<0.01%的巴西人口接种。
联邦政府必须评估这些障碍，并提出解决方案，以最大限度地提高巴西对 COVID-19 的免疫接种率。
